Asundexian: 10 Key Facts on the First Factor XIa Inhibitor Approved to Prevent Repeat Stroke

FDA approval of Bayer’s asundexian (Sunharbo) for people after a mild-to-moderate ischaemic stroke or high-risk TIA: how it works, the OCEANIC-STROKE results, bleeding risk, cost and who it’s for.

·

·

8–13 minutes

·

Edited by Joshua Adebanjo, RN

Asundexian: New Drug to Prevent Repeat Stroke

The US Food and Drug Administration (FDA) has approved asundexian, sold as Sunharbo, the first of a new class of medicines called factor XIa inhibitors, to reduce the risk of another stroke in people who have recently had a mild-to-moderate ischaemic stroke or a high-risk transient ischaemic attack (TIA).

Bayer announced the approval on 9 November 2026. In the OCEANIC-STROKE trial, adding asundexian to standard antiplatelet treatment reduced ischaemic strokes by a relative 26% over two years compared with placebo, without increasing major bleeding. This matters because more intensive blood-thinning has always carried a higher risk of serious bleeding. Asundexian is not approved for people with atrial fibrillation. It was approved in China in October and is under review in Europe and Japan.

asundexian

Imagine a 64-year-old shopkeeper who had a small stroke three months ago. He recovered well, but he lives with the fear that another one could come at any time. He already takes an antiplatelet tablet, a cholesterol medicine and blood pressure treatment. At his follow-up, his stroke nurse explains that a new medicine has been approved in some countries that works in a different way, reducing the risk of clots forming without greatly increasing the risk of serious bleeding. They talk through the benefits, the side effects and the cost. Whether or not it is right for him, he leaves feeling that more options are opening up for people like him.

What happened

On 9 November 2026, Bayer announced that the FDA had approved asundexian (Sunharbo). The FDA’s novel drug approvals list records the approval date as 9 November.

Asundexian is approved for adults who have had a recent non-cardioembolic ischaemic stroke, meaning a stroke caused by a blocked artery but not by a clot from the heart, with a severity score (NIHSS) of 15 or less, or a high-risk TIA, and who are taking antiplatelet therapy. It is not approved for people with atrial fibrillation.

The approval was based on the OCEANIC-STROKE trial. Bayer expects to begin shipping the medicine in the US in November, with a list price of $748.50 for a 30-day supply. Asundexian was approved in China in October 2026 and is under review in Europe and Japan.

10 key facts

  1. The FDA has approved asundexian (Sunharbo) to reduce repeat stroke risk.
  2. It is the first approved factor XIa inhibitor.
  3. It is for adults after a recent mild-to-moderate ischaemic stroke or high-risk TIA.
  4. It is taken alongside antiplatelet treatment.
  5. It reduced ischaemic strokes by a relative 26% over two years.
  6. The absolute reduction was 2.2 percentage points.
  7. There was no increase in major bleeding in the trial.
  8. Gastrointestinal bleeding was slightly more common.
  9. It is not approved for people with atrial fibrillation.
  10. It is also approved in China and under review in Europe and Japan.

The numbers at a glance

  • Approved: 9 November 2026 (US)
  • Relative reduction in ischaemic stroke: 26%
  • Absolute reduction: 2.2 percentage points over 2 years
  • No increase in ISTH major bleeding
  • Gastrointestinal bleeding: 2.7 vs 2.1 per 100 patient-years
  • Diarrhoea: 3.4% vs 2.8% on placebo
  • US list price: $748.50 for 30 days
  • For strokes with NIHSS score of 15 or less

How does asundexian work?

Blood clots form through a chain of reactions involving proteins called clotting factors. Most current anticoagulants block factors that are essential both for stopping bleeding after an injury and for forming harmful clots inside blood vessels. That’s why they increase bleeding risk.

Factor XI (eleven) appears to play a bigger role in the growth of harmful clots than in normal healing. People born with low factor XI levels have fewer strokes and clots but usually only mild bleeding problems. Medicines that block activated factor XI (factor XIa) aim to prevent dangerous clots while preserving the body’s ability to stop bleeding.

Asundexian is a tablet taken once a day. It is the first medicine in this new class to be approved, and several others are being tested for different conditions.

Why this matters

People who have had an ischaemic stroke or TIA face a high risk of another stroke, especially in the first months. Current prevention combines antiplatelet medicines, blood pressure control, cholesterol-lowering treatment and lifestyle changes, but some people still have further strokes.

Adding stronger blood thinners has usually meant more serious bleeding, including brain bleeds. A medicine that lowers stroke risk without increasing major bleeding could change secondary stroke prevention.

Experts say guidelines will need to be updated, and cost may limit access.

What officials and experts said

Dr Ashkan Shoamanesh, co-principal investigator of OCEANIC-STROKE, said asundexian ‘offers physicians a new opportunity to provide greater protection against recurrent stroke without the bleeding penalty that has historically limited more intensive antithrombotic treatment’. He named guideline incorporation, education and fair reimbursement as next steps.

Dr Cheryl Bushnell said cost is ‘probably going to be the main limiting factor’.

What this means for you

  • If you’ve had a stroke or TIA, keep taking your prescribed medicines; don’t stop or switch without advice.
  • Ask your stroke team whether asundexian might be suitable and available where you live.
  • Tell your care team about all medicines, as some interact with asundexian.
  • Report signs of bleeding, such as black stools or unusual bruising.
  • Control blood pressure, cholesterol and diabetes, stop smoking and stay active.
  • Learn the FAST signs of stroke and call emergency services immediately if they appear.

What this means for nurses and health workers

Stroke nurses will play a key role in helping patients understand new treatment options and in monitoring safety.

  • Explain how asundexian differs from other blood thinners.
  • Check for interacting medicines and liver problems.
  • Teach patients to recognise bleeding.
  • Reinforce adherence to all stroke prevention medicines.
  • Support lifestyle changes.
  • Report suspected side effects.

The global picture

Stroke is a leading cause of death and disability worldwide, with most of the burden in low- and middle-income countries. New medicines often reach high-income countries first. Asundexian is now approved in the US and China, with reviews under way in Europe and Japan.

Who should not take it

Asundexian is not recommended with certain medicines that strongly speed up drug breakdown (combined P-glycoprotein and strong CYP3A4 inducers), or in people with moderate or severe liver impairment. It is considered unsuitable for people with end-stage kidney disease. Raised liver enzymes have been seen, mostly mild. Your care team will check whether it is safe for you.

Atrial fibrillation is different

People whose stroke was caused by atrial fibrillation usually need anticoagulants such as apixaban or warfarin. Asundexian is not approved for this group.

Other ways to prevent another stroke

Medicines work best alongside healthy habits: controlling blood pressure, eating well, being active, limiting alcohol and stopping smoking.

Cost and access

Bayer says actual costs depend on insurance and that some patients may receive the medicine free through its patient assistance foundation. Availability in other countries will depend on regulatory approval and pricing.

What is a TIA?

A transient ischaemic attack causes stroke symptoms that resolve within minutes or hours. It is a warning that a stroke may follow and needs urgent assessment.

A new era of blood thinners

Several factor XI and XIa inhibitors are in trials for conditions such as atrial fibrillation, heart attack and preventing clots after surgery.

Questions about switching treatment

New medicines often generate interest, and some people may wonder whether to change their current treatment. It is important not to stop or switch any stroke prevention medicine without talking to your care team, as gaps in treatment can increase stroke risk. Asundexian is added to antiplatelet therapy rather than replacing it, and it is only approved for specific groups of patients. Your nurse or healthcare provider can explain whether you meet the criteria, how the medicine fits with your other treatments, what monitoring is needed, and whether it is available and affordable where you live. Bringing a list of all your medicines, including over-the-counter and herbal remedies, to the appointment helps them check for interactions.

Myths and facts

Myth: Stronger blood thinners always mean more bleeding.
Fact: Asundexian did not increase major bleeding in its trial.

Myth: New medicines replace healthy habits.
Fact: Lifestyle changes remain essential.

Myth: Asundexian is for all stroke patients.
Fact: It is for specific groups, not atrial fibrillation.

Myth: I can stop my other medicines.
Fact: Asundexian is added to antiplatelet treatment.

Questions and answers

What is asundexian?

A factor XIa inhibitor to lower repeat stroke risk.

Who is it for?

Adults after a mild-to-moderate ischaemic stroke or high-risk TIA.

How effective is it?

It cut ischaemic strokes by 26% in relative terms over two years.

Does it cause bleeding?

Major bleeding did not increase, but GI bleeding was slightly more common.

Is it available outside the US?

It is approved in China and under review elsewhere.

Can people with atrial fibrillation use it?

No, it is not approved for them.

How much does it cost?

The US list price is $748.50 for 30 days.

What happens next

Asundexian is expected to reach US pharmacies in November. Decisions are pending in Europe and Japan, and stroke guidelines may be updated to include it. Other factor XI medicines are being tested for different conditions.

Key takeaways

  • The FDA has approved asundexian (Sunharbo) to reduce repeat stroke risk.
  • It is for adults after a recent mild-to-moderate ischaemic stroke or high-risk TIA.
  • It reduced ischaemic strokes by a relative 26% over two years.
  • There was no increase in major bleeding in the trial.
  • It is not approved for people with atrial fibrillation.
  • It is also approved in China and under review in Europe and Japan.

How we report health news

Nursing Media Network reports health news using official sources such as the World Health Organization, national public health agencies, medicines regulators and peer-reviewed research, which are linked at the end of each story. Figures in fast-moving stories, such as outbreaks, change quickly, so we state the date each number refers to. If you are reading this later, check the latest update from the official source before making decisions.

News reports describe what has happened across a population. They cannot tell you what is right for your own health. If a story raises questions about your treatment, symptoms or risk, speak to your nurse or healthcare provider before making any changes.

Staying informed without feeling overwhelmed

A constant stream of health headlines can leave people anxious or confused. It can help to choose one or two trusted sources and check them at set times, rather than scrolling throughout the day. Focus on what you can control, such as vaccinations, regular check-ups, healthy routines and knowing when to seek care. Talk about worries with family, friends or your nurse rather than keeping them to yourself, and take a break from news if it is affecting your sleep or mood. Being informed is useful; being overwhelmed is not.

Finding reliable health information

Health information online varies widely in quality. Prefer sources such as the World Health Organization, national health ministries, public health agencies, university hospitals and registered professional bodies. Be cautious with social media posts, miracle cures and products sold with promises that sound too good to be true.

If you read something that worries you or contradicts the advice you have been given, write it down and discuss it with your nurse or healthcare provider. They can explain how it applies to your own situation and help you separate evidence from rumour.

Questions to ask your nurse or healthcare provider

  • Is asundexian suitable for me?
  • How does it fit with my current medicines?
  • What side effects should I watch for?
  • Does it interact with my other medicines?
  • Is it available and affordable here?
  • What else can I do to prevent another stroke?

But don’t all blood thinners raise bleeding risk?

Most do. Asundexian works differently, and in its main trial it lowered stroke risk without increasing major bleeding.

Your next step: If you’ve had a stroke or TIA, book a review with your stroke nurse to discuss your prevention plan, including whether new treatments might help.

Related: TIA · Carotid artery disease · Stroke

Sources: TCTMD; FDA: novel drug approvals 2026.

Joshua Ibukunoluwa Adebanjo

Founder & Editor-in-Chief

Joshua Ibukunoluwa Adebanjo

RN, RM, RPHN, BNSc (Obafemi Awolowo University)

Joshua is a registered nurse, midwife and public health nurse with clinical experience at Obafemi Awolowo University Teaching Hospitals Complex. He founded Nursing Media Network to give nurses worldwide trustworthy news, career guidance and a stronger public voice, and leads its editorial direction.

Full profile · Editorial policy · joshuadebanjo.com

Health information on Nursing Media Network is for education and does not replace advice from your own nurse or healthcare provider.

Leave a Reply

Most read

Discover more from Nursing Media Network

Subscribe now to keep reading and get access to the full archive.

Continue reading